Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 8, 2009, Pages 902-914

  Miners, James Scott ^a   Baig, Shabnam ^a   Tayler, Hannah ^a   Kehoe, Patrick Gavin ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer disease; Amyloid A peptide; Apolipoprotein E; Insulin degrading enzyme; Neprilysin; Neuron specific enolase

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; MEMBRANE METALLOENDOPEPTIDASE; APOLIPOPROTEIN E4; ENOLASE; INSULINASE;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CELL SPECIFICITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; NERVE CELL; NERVE DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; AGE; AGED; ANALYSIS OF VARIANCE; BRAIN; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULYSIN; MALE; NEPRILYSIN; PHOSPHOPYRUVATE HYDRATASE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 69449102820     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181afe475     Document Type: Article

References (53)

1. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992;256:184-185
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-498
3. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253-266
4. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 2008;14:1601-1605
5. Carson JA, Turner AJ. Beta-amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002;81:1-8
6. Turner AJ, Fisk L, Nalivaeva NN. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann N Y Acad Sci 2004;1035:1-20
7. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-159
8. Tyler SJ, Dawbarn D, Wilcock GK, et al. alpha- and beta-secretase: Profound changes in Alzheimer's disease. Biochem Biophys Res Commun 2002;299:373-376
9. Zhao J, Fu Y, Yasvoina M, et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis. J Neurosci 2007;27:3639-3649
10. Wang DS, Dickson DW, Malter JS. Beta-amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006;2006:58406
11. Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006;281: 30471-30478
12. Iwata N, Mizukami H, Shirotani K, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 2004;24:991-998
13. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001;292:1550-1552
14. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the betaamyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003;100:4162-4167
15. Miller BC, Eckman EA, Sambamurti K, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A 2003;100:6221-6226
16. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003;40:1087-1093
17. Marr RA, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23:1992-1996
18. Hemming ML, Patterson M, Reske-Nielsen C, et al. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: A novel therapeutic approach to Alzheimer disease. PLoS Med 2007;4:e362
19. El-Amouri SS, Zhu H, Yu J, et al. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007;1152:191-200
20. El-Amouri SS, Zhu H, Yu J, et al. Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 2008;172: 1342-1354
21. Poirier R, Wolfer DP, Welzl H, et al. Neuronal neprilysin overexpression is associated with attenuation of A(-related spatial memory deficit. Neurobiol Dis 2006;24:475-83
22. Carpentier M, Robitaille Y, DesGroseillers L, et al. Declining expression of neprilysin in Alzheimer disease vasculature: Possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002;61:849-856
23. Miners JS, Van Helmond Z, Chalmers K, et al. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006;65: 1012-1021
24. Miners JS, Baig S, Palmer J, et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18:240-252
25. Perez A, Morelli L, Cresto JC, et al. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000;25:247-255
26. Zhao Z, Xiang Z, Haroutunian V, et al. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 2007;28: 824-830
27. Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Abeta levels. Neurobiol Aging 2008;29:210-221
28. Caccamo A, Oddo S, Sugarman MC, et al. Age- and region-dependent alterations in Abeta-degrading enzymes: Implications for Abeta-induced disorders. Neurobiol Aging 2005;26:645-654
29. Carter TL, Pedrini S, Ghiso J, et al. Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis. Neurosci Lett 2006;392:235-239
30. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162:313-319
31. Harada H, Tamaoka A, Ishii K, et al. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci Res 2006;54:24-29
32. Miners JS, Verbeek MM, Rikkert MO, et al. Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 2008;167:229-236
33. Miners JS, Kehoe PG, Love S. Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. J Neurosci Methods 2008;169:177-181
34. Akiyama H, Kondo H, Ikeda K, et al. Immunohistochemical localization of neprilysin in the human cerebral cortex: Inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res 2001;902:277-281
35. Yasojima K, Akiyama H, McGeer EG, et al. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 2001;297:97-100
36. Wang DS, Lipton RB, Katz MJ, et al. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 2005;64:378-385
37. Russo R, Borghi R, Markesbery W, et al. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett 2005;579: 6027-6030
38. Maruyama M, Higuchi M, Takaki Y, et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 2005;57: 832-842
39. Apelt J, Ach K, Schliebs R. Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett 2003;339: 183-186
40. Leal MC, Dorfman VB, Gamba AF, et al. Plaque-associated over-expression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol 2006;65:976-987
41. Vepsalainen S, Hiltunen M, Helisalmi S, et al. Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's 216-220
42. Deb S, Zhang JW, Gottschall PE. Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to beta-amyloid peptide. J Neurosci Res 1999;55:44-53
43. Jung SS, Zhang W, Van Nostrand WE. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 2003;85:1208-1215
44. Lee JM, Yin KJ, Hsin I, et al. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 2003;54:379-382
45. Tucker HM, Kihiko-Ehmann M, Wright S, et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem 2000;75:2172-2177
46. Iijima-Ando K, Hearn SA, Granger L, et al. Overexpression of neprilysin reduces Alzheimer amyloid-beta42 (Abeta42)Yinduced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding proteinYmediated transcription, agedependent axon pathology, and premature death in Drosophila. J Biol Chem 2008;283:19066-19076
47. Pardossi-Piquard R, Petit A, Kawarai T, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 2005;46:541-554
48. Chen AC, Selkoe DJ. Response to: Pardossi-Piquard et al. BPresenilin- Dependent Transcriptional Control of the Abeta-Degrading Enzyme Neprilysin by Intracellular Domains of betaAPP and APLP.[ Neuron 46, 541-554
49. Neuron 2007;53:479-83
50. Ganju RK, Shpektor RG, Brenner DG, et al. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn srcYrelated kinase. Blood 1996; 88:4159-4165
51. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008;104:1433-1439
52. Saito T, Iwata N, Tsubuki S, et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 2005;11:434-439
53. Grouselle D, Winsky-Sommerer R, David JP, et al. Loss of somatostatinlike immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett 1998;255: 21-24